Breakthrough Data from EADV 2026 Reveals Insight into DecisionDx-Melanoma and Surgical Management Benefits

Late-Breaking Data at EADV 2026: The Role of DecisionDx®-Melanoma

Castle Biosciences, a pioneering diagnostics firm, recently showcased groundbreaking data at the European Academy of Dermatology and Venereology (EADV) Congress 2026, held in Vienna from September 30 to October 3. Their findings regarding DecisionDx-Melanoma provide vital insights into its function in sentinel lymph node biopsy (SLNB) decision-making and enhanced patient management.

In particular, the research highlighted the largest prospective, multi-center evaluation of gene expression profiling (GEP) for cutaneous melanoma, comprising 2,799 patients from 29 centers across the United States. The data revealed that patients classified with low-risk DecisionDx-Melanoma i31-SLNB results exhibited an exceptionally low SLN positivity rate of 4.4%, significantly aligning with the test's predicted risk of under 5%. More impressively, eligible patients who opted out of SLNB exhibited a remarkable five-year recurrence-free survival (RFS) rate of 99.6%.

Dr. Joseph Gadzia, a board-certified dermatologist and Mohs micrographic surgeon, articulated the importance of these findings. He explained that while staging is critical, understanding tumor biology through DecisionDx-Melanoma can greatly enhance the quality of care and reduce unnecessary interventions. The results from this extensive study instill confidence in physicians, permitting them to make informed decisions regarding SLNB and follow-up care based on individual patient data.

Important Findings and Implications

Integrated 31-Gene Expression Profile (i31-SLNB) Insights

The presentation's first key component was an abstract focusing on how the i31-SLNB can effectively identify low-risk patients, thereby affirming their ability to avoid SLNB. Conversely, patients classified with a high risk (greater than 10% predicted risk) had a notably higher observed SLN positivity rate of 22.8%. This dual capability of the test to discern both low and high-risk patients offers a more tailored approach to melanoma management.

In another revealing part of the presentation, it was shown that DecisionDx-Melanoma’s 31-GEP Class results provided prognostic metrics beyond traditional staging methods. For instance, patients at early stages (stage I-IIA) who received high-risk Class 2B results exhibited an RFS similar to those diagnosed with stage IIB disease. This finding calls for a reevaluation of monitoring and treatment protocols, advocating for heightened vigilance in cases where initial staging signals uncertainty.

Furthermore, a secondary abstract shared through an ePoster detailed the ramifications of tumor transection during biopsies. The study involved 687 patients with transected melanomas, demonstrating that DecisionDx-Melanoma could discriminate recurrence risks effectively, with low-risk Class 1A patients achieving a five-year RFS rate of 93.2%, juxtaposed with 64.1% among high-risk Class 2B counterparts. This underscores the test’s potential to enhance follow-up care strategies based on informed risk assessments.

Supporting Technology: AdvanceAD-Tx™

Additionally, Castle Biosciences reiterated previous findings on its AdvanceAD-Tx™ test, which is designed for atopic dermatitis treatment. This tool evaluates a 487-gene expression profile from lesional skin scraping samples to assist clinicians in selecting the most effective systemic therapies.

Conclusion: Shaping the Future of Melanoma Management

Castle Biosciences’ presentations at EADV 2026 not only highlighted significant clinical findings on DecisionDx-Melanoma and AdvanceAD-Tx but also emphasized the company's commitment to refining healthcare through dual innovation strategies. The ability of DecisionDx-Melanoma to enhance decision-making while allowing for tailored post-surgical management solidifies its position as a game-changing tool in combating cutaneous melanoma. For more details, visit Castle Biosciences.